ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cilofexor

Also written as “Cilofexor”, “CILO” and “Cilofexor Dose B”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Cholangitis, Sclerosing · Liver Cirrhosis, Biliary, led by 2 companies.

Drug pageCilofexor: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 25, 201913 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences121 open or runningphase 3since Mar 25, 2019Jan 11, 2016Dec 2028phase 2 · NCT07841977
Phenex Pharmaceuticalsits history only10 open or runningphase 2since Nov 19, 2013Nov 19, 2013none ahead

Also a collaborator on its studies: Novo Nordisk.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Gilead Sciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jan 11, 2016First study: phase 1 study in Non-alcoholic Fatty Liver DiseaseFirst studyNCT02654002 · 120 enrolled · United States
  2. May 20, 2016Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT02781584 · 220 enrolled · United States, New Zealand
  3. Jun 13, 20162 phase 2 studiesNCT02943460, NCT02943447
  4. Jun 17, 2016Phase 1 study in Non-alcoholic Fatty Liver DiseaseNCT02808312 · 57 enrolled · United States, New Zealand
  5. Jul 29, 2016Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT02854605 · 140 enrolled · United States, Canada, Hong Kong and more
  6. Dec 9, 2017Named cilofexorINNProposed as its International Nonproprietary Name in WHO's List 118
  7. Feb 23, 2018Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03449446 · 395 enrolled · United States, Australia, Canada and more
  8. Mar 25, 2019Phase 3 study in Cholangitis, SclerosingNCT03890120 · 419 enrolled · United States, Australia, Austria and more
  9. Jun 12, 2019Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT03987074 · 109 enrolled · United States
  10. Aug 15, 2019Phase 1 study in Cholangitis, SclerosingNCT04060147 · 11 enrolled · United States
  11. Jul 20, 2021Phase 2 study in Non-alcoholic Fatty Liver DiseaseNCT04971785 · 457 enrolled · United States, Australia, Canada and more
  12. Sep 21, 2026Phase 2 study in Liver Cirrhosis, BiliaryNCT07841977 · 132 planned · United States

Ahead

  1. Dec 2028Primary completion: phase 2 study in Liver Cirrhosis, BiliaryNCT07841977

TargetBeta

NR1H4 →read by rule
“Bile acid receptor FXR agonist”ChEMBL 37, by rule

Other programs on NR1H4

ProgramCompanyFurthest phaseStudies
LY4395089Eli Lillyphase 23

Studies

All 12 Gilead Sciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07841977Liver Cirrhosis, Biliary · United States2RecruitingDec 2028132
NCT04971785Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more2CompletedNov 12, 2024457
NCT04060147Cholangitis, Sclerosing · United States1TerminatedSep 2, 202111
NCT03987074Non-alcoholic Fatty Liver Disease · United States2CompletedJul 13, 2020109
NCT03890120Cholangitis, Sclerosing · United States, Australia, Austria and more3TerminatedNov 10, 2022419
NCT03449446Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more2CompletedOct 30, 2019395
NCT02854605Non-alcoholic Fatty Liver Disease · United States, Canada, Hong Kong and more2CompletedJan 9, 2018140
NCT02808312Non-alcoholic Fatty Liver Disease · United States, New Zealand1CompletedOct 16, 201857
NCT02943460Cholangitis, Sclerosing · United States, Austria, Canada and more2CompletedFeb 28, 201852
NCT02943447Liver Cirrhosis, Biliary · United States, Austria, Canada and more2TerminatedSep 4, 201971
NCT02781584Non-alcoholic Fatty Liver Disease · United States, New Zealand2CompletedDec 17, 2020220
NCT02654002Non-alcoholic Fatty Liver Disease · United States1CompletedJul 14, 2016120

How it is read

Names in the registry

  • “Cilofexor”, 7 entries
  • “CILO”, 2 entries
  • “Cilofexor Dose B”, 1 entry
  • “Cilofexor Dose A”, 1 entry
  • “Cilofexor (CILO)/Firsocostat (FIR)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.